Altamira Therapeutics Publishes Preclinical Data For Treatment Of Abdominal Aortic Aneurysm With SOD2 mRNA Delivered By SemaPhore Nanoparticles
$CYTO
Biotechnology: Pharmaceutical Preparations
Health Care
- Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic aneurysm
- Altamira's SemaPhore™ nanoparticles delivering SOD2 mRNA successfully to mitochondria in aorta wall
- Positive outcomes suggest potential use of treatment in management of small abdominal aortic aneurysm and prevention of ruptures